Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy.

abstract：:Infectious agents play an etiologic role in approximately 20% of cancer cases worldwide. Eleven pathogens (seven viruses, three parasites, and one bacterium) are known to contribute to oncogenesis either directly via the expression of their protein products or indirectly via chronic inflammation. Although prevention o...

journal_title：Cancer immunology research

authors： Vandeven N,Nghiem P

更新日期：2014-01-01 00:00:00

abstract：:Programmed death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors have shown activity in metastatic clear cell renal cell carcinoma (ccRCC). Data on the activity of these agents in patients with non-clear cell RCC (nccRCC) or patients with sarcomatoid/rhabdoid differentiation are limited. In this multicenter analysis, we e...

journal_title：Cancer immunology research

authors： McKay RR,Bossé D,Xie W,Wankowicz SAM,Flaifel A,Brandao R,Lalani AA,Martini DJ,Wei XX,Braun DA,Van Allen E,Castellano D,De Velasco G,Wells JC,Heng DY,Fay AP,Schutz FA,Hsu J,Pal SK,Lee JL,Hsieh JJ,Harshman LC,Si

更新日期：2018-07-01 00:00:00

abstract：:The current standard of care for treatment of metastatic renal cell carcinoma (mRCC) patients is PD-1/PD-L1 inhibitors until progression or toxicity. Here, we characterize the clinical outcomes for 19 mRCC patients who experienced an initial clinical response (any degree of tumor shrinkage), but after immune-related a...

journal_title：Cancer immunology research

authors： Martini DJ,Hamieh L,McKay RR,Harshman LC,Brandao R,Norton CK,Steinharter JA,Krajewski KM,Gao X,Schutz FA,McGregor B,Bossé D,Lalani AA,De Velasco G,Michaelson MD,McDermott DF,Choueiri TK

更新日期：2018-04-01 00:00:00

abstract：:The FDA-AACR Oncology Dose-Finding Workshop, Part 3, was held in Washington, DC, on July 20, 2017, as a continuation of the previous two collaborative dose-finding and optimization workshops presented by the FDA and AACR. This year's workshop focused on combination therapy with immune-oncology agents and best practice...

journal_title：Cancer immunology research

authors： Emens LA,Bruno R,Rubin EH,Jaffee EM,McKee AE

更新日期：2017-12-01 00:00:00

abstract：:Macrophage-mediated cytotoxicity is controlled by surface receptor expression and activation. Despite the numerous studies documenting the role of macrophage C-type lectin receptors (CLR) in pathogen elimination, little is known about their contribution to antitumor responses. Here, we report that IL13 inhibits T-cell...

journal_title：Cancer immunology research

authors： Alaeddine M,Prat M,Poinsot V,Gouazé-Andersson V,Authier H,Meunier E,Lefèvre L,Alric C,Dardenne C,Bernad J,Alric L,Segui B,Balard P,Couderc F,Couderc B,Pipy B,Coste A

更新日期：2019-02-01 00:00:00

abstract：:Blockade of the pathway including programmed death-ligand 1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) has produced clinical benefits in patients with a variety of cancers. Elevated levels of soluble PD-L1 (sPD-L1) have been associated with worse prognosis in renal cell carcinoma and multiple myel...

journal_title：Cancer immunology research

authors： Zhou J,Mahoney KM,Giobbie-Hurder A,Zhao F,Lee S,Liao X,Rodig S,Li J,Wu X,Butterfield LH,Piesche M,Manos MP,Eastman LM,Dranoff G,Freeman GJ,Hodi FS

更新日期：2017-06-01 00:00:00

abstract：:Cancer immunology has recently made major therapeutic inroads that represent clinical application of basic insights into mechanisms that govern immunity against tumors. Research into fundamental elements of T-cell and natural killer-cell biology, including the basis of antigen recognition, activation, proliferation, a...

journal_title：Cancer immunology research

authors： Kim HJ,Cantor H

更新日期：2014-10-01 00:00:00

abstract：:Many immunotherapeutic approaches under development rely on T-cell recognition of cancer-derived peptides bound to human leukocyte antigen molecules on the cell surface. Direct experimental demonstration that such peptides are processed and bound is currently challenging. Here, we describe a method that meets this cha...

journal_title：Cancer immunology research

authors： Wang Q,Douglass J,Hwang MS,Hsiue EH,Mog BJ,Zhang M,Papadopoulos N,Kinzler KW,Zhou S,Vogelstein B

更新日期：2019-11-01 00:00:00

abstract：:Antibody-drug conjugates (ADC) are emerging as powerful treatment strategies with outstanding target-specificity and high therapeutic activity in patients with cancer. Brentuximab vedotin represents a first-in-class ADC directed against CD30(+) malignancies. We hypothesized that its sustained clinical responses could ...

journal_title：Cancer immunology research

authors： Müller P,Martin K,Theurich S,Schreiner J,Savic S,Terszowski G,Lardinois D,Heinzelmann-Schwarz VA,Schlaak M,Kvasnicka HM,Spagnoli G,Dirnhofer S,Speiser DE,von Bergwelt-Baildon M,Zippelius A

更新日期：2014-08-01 00:00:00

abstract：:Cancer-testis (CT) antigens are attractive tumor antigens for cancer immunotherapy. They comprise a group of proteins normally expressed in germ cells and aberrantly activated in a variety of human cancers. The protein expression of eight cancer-testis antigens [MAGEA, NY-ESO-1, GAGE, MAGEC1 (CT7), MAGEC2 (CT10), CT45...

journal_title：Cancer immunology research

authors： Chen YT,Panarelli NC,Piotti KC,Yantiss RK

更新日期：2014-05-01 00:00:00

abstract：:Chimeric antigen receptor (CAR) T-cell therapy is effective in the treatment of cancers of hematopoietic origin. In the immunosuppressive solid tumor environment, CAR T cells encounter obstacles that compromise their efficacy. We developed a strategy to address these barriers by having CAR T cells secrete single-domai...

journal_title：Cancer immunology research

authors： Xie YJ,Dougan M,Ingram JR,Pishesha N,Fang T,Momin N,Ploegh HL

更新日期：2020-04-01 00:00:00

abstract：:CD47-specific antibodies and fusion proteins that block CD47-SIRPα signaling are employed as antitumor agents for several cancers. Here, we investigated the synergistic antitumor effect of simultaneously targeting CD47 and autophagy in non-small cell lung cancer (NSCLC). SIRPαD1-Fc, a novel CD47-targeting fusion prote...

journal_title：Cancer immunology research

authors： Zhang X,Fan J,Wang S,Li Y,Wang Y,Li S,Luan J,Wang Z,Song P,Chen Q,Tian W,Ju D

更新日期：2017-05-01 00:00:00

abstract：:The presence of regulatory T cells (Treg) in solid tumors is known to play a role in patient survival in ovarian cancer and other malignancies. We assessed inherited genetic variations via 749 tag single-nucleotide polymorphisms (SNP) in 25 Treg-associated genes (CD28, CTLA4, FOXP3, IDO1, IL10, IL10RA, IL15, 1L17RA, I...

journal_title：Cancer immunology research

authors： Charbonneau B,Moysich KB,Kalli KR,Oberg AL,Vierkant RA,Fogarty ZC,Block MS,Maurer MJ,Goergen KM,Fridley BL,Cunningham JM,Rider DN,Preston C,Hartmann LC,Lawrenson K,Wang C,Tyrer J,Song H,deFazio A,Johnatty SE,Doher

更新日期：2014-04-01 00:00:00

abstract：:Individuals of African descent are disproportionately affected by specific complex diseases, such as breast and prostate cancer, which are driven by both biological and nonbiological factors. In the case of breast cancer, there is clear evidence that psychosocial factors (environment, socioeconomic status, health beha...

journal_title：Cancer immunology research

authors： Yeyeodu ST,Kidd LR,Kimbro KS

更新日期：2019-09-01 00:00:00

abstract：:Chronic lymphocytic leukemia (CLL) is a B-cell neoplasia characterized by protumor immune dysregulation involving nonmalignant cells of the microenvironment, including T lymphocytes and tumor-associated myeloid cells. Although therapeutic agents have improved treatment options for CLL, many patients still fail to resp...

journal_title：Cancer immunology research

authors： Banerjee P,Zhang R,Ivan C,Galletti G,Clise-Dwyer K,Barbaglio F,Scarfò L,Aracil M,Klein C,Wierda W,Plunkett W,Caligaris-Cappio F,Gandhi V,Keating MJ,Bertilaccio MTS

更新日期：2019-12-01 00:00:00

abstract：:Despite the rapid progress in the development of novel adoptive T-cell therapies, the clinical benefits in treatment of established tumors have remained modest. Several immune evasion mechanisms hinder T-cell entry into tumors and their activity within the tumor. Of note, oncolytic adenoviruses are intrinsically immun...

journal_title：Cancer immunology research

authors： Tähtinen S,Grönberg-Vähä-Koskela S,Lumen D,Merisalo-Soikkeli M,Siurala M,Airaksinen AJ,Vähä-Koskela M,Hemminki A

更新日期：2015-08-01 00:00:00

abstract：:Vaccination of patients with ovarian cancer with overlapping long peptides (OLP) from cancer-testis antigen NY-ESO-1 and poly-ICLC in Montanide-ISA-51 (Montanide) was found to consistently induce integrated immune responses (antibody, CD4(+), and CD8(+) T cells). Using detailed methods, we investigated the respective ...

journal_title：Cancer immunology research

authors： Tsuji T,Sabbatini P,Jungbluth AA,Ritter E,Pan L,Ritter G,Ferran L,Spriggs D,Salazar AM,Gnjatic S

更新日期：2013-11-01 00:00:00

abstract：:Recruitment of myeloid-derived suppressor cells (MDSC) into the tumor microenvironment (TME) contributes to cancer immune evasion. MDSCs express the chemokine receptor CXCR2, and inhibiting CXCR2 suppresses the recruitment of MDSCs into the tumor and the premetastatic niche. Here, we compared the growth and metastasis...

journal_title：Cancer immunology research

authors： Yang J,Yan C,Vilgelm AE,Chen SC,Ayers GD,Johnson CA,Richmond A

更新日期：2020-11-11 00:00:00

abstract：:Despite HER2-targeted therapies improving the outcome of HER2+ breast cancer, many patients experience resistance and metastatic progression. Cancer stem cells (CSC) play a role in this resistance and progression, thus combining HER2 targeting with CSC inhibition could improve the management of HER2+ breast cancer. Th...

journal_title：Cancer immunology research

authors： Conti L,Bolli E,Di Lorenzo A,Franceschi V,Macchi F,Riccardo F,Ruiu R,Russo L,Quaglino E,Donofrio G,Cavallo F

更新日期：2020-08-01 00:00:00

abstract：:In hepatocellular carcinoma (HCC), surgical resection is associated with high recurrence rate, and no effective adjuvant therapy currently exists. We initiated a pilot randomized trial of perioperative immunotherapy with nivolumab and ipilimumab for resectable HCC. Here, we provide an illustrative report of a case tha...

journal_title：Cancer immunology research

authors： Kaseb AO,Vence L,Blando J,Yadav SS,Ikoma N,Pestana RC,Vauthey JN,Allison JP,Sharma P

更新日期：2019-09-01 00:00:00

abstract：:Tumors use various mechanisms to avoid immune destruction. Cyclooxygenase-2 (COX-2) expression may be a driver of immune suppression in melanoma, but the mechanisms involved remain elusive. Here, we show that COX-2 expression drives constitutive expression of indoleamine 2,3-dioxygenase 1 (IDO1) in human tumor cells. ...

journal_title：Cancer immunology research

authors： Hennequart M,Pilotte L,Cane S,Hoffmann D,Stroobant V,Plaen E,Van den Eynde BJ

更新日期：2017-08-01 00:00:00

abstract：:Regulatory T cells (Treg) have long been considered one-sided suppressors of antitumor immune responses and hence associated with poor patient outcome in cancer. However, evidence is mounting of a paradoxical positive prognostic effect of Tregs on certain malignancies, including urinary bladder cancer (UBC). This disc...

journal_title：Cancer immunology research

authors： Winerdal ME,Krantz D,Hartana CA,Zirakzadeh AA,Linton L,Bergman EA,Rosenblatt R,Vasko J,Alamdari F,Hansson J,Holmström B,Johansson M,Winerdal M,Marits P,Sherif A,Winqvist O

更新日期：2018-05-01 00:00:00

abstract：:MHC-bound peptides from aberrant proteins may be a specific immunotherapeutic target on cancer cells. Because of difficulties in identifying such antigens, viral or model antigens have so far been used to study their biological relevance. We here identify a naturally existing human T-cell epitope derived from a trunca...

journal_title：Cancer immunology research

authors： Pont MJ,Oostvogels R,van Bergen CAM,van der Meijden ED,Honders MW,Bliss S,Jongsma MLM,Lokhorst HM,Falkenburg JHF,Mutis T,Griffioen M,Spaapen RM

更新日期：2019-05-01 00:00:00

abstract：:Human papillomavirus type 16 (HPV16) is the etiologic factor for cervical cancer and a subset of oropharyngeal cancers. Although several prophylactic HPV vaccines are available, no effective therapeutic strategies to control active HPV diseases exist. Tumor implantation models are traditionally used to study HPV-assoc...

journal_title：Cancer immunology research

authors： Lin YH,Yang MC,Tseng SH,Jiang R,Yang A,Farmer E,Peng S,Henkle T,Chang YN,Hung CF,Wu TC

更新日期：2018-03-01 00:00:00

abstract：:Efficacious antitumor immune responses must overcome multiple suppressive mechanisms in the tumor microenvironment to control cancer progression. In this study, we demonstrate that dual targeting of suppressive myeloid populations by inhibiting CSF-1/CSF-1R signaling and activation of antigen-presenting cells with ago...

journal_title：Cancer immunology research

authors： Wiehagen KR,Girgis NM,Yamada DH,Smith AA,Chan SR,Grewal IS,Quigley M,Verona RI

更新日期：2017-12-01 00:00:00

abstract：:Radiotherapy (RT) represents one of the main anticancer approaches for the treatment of solid tumors. Beyond the expected direct effects of RT on tumor cells, evidence supporting the importance of an immune response to RT is growing. The balance between RT-mediated immunogenic and tolerogenic activity is ill-defined a...

journal_title：Cancer immunology research

authors： Mondini M,Loyher PL,Hamon P,Gerbé de Thoré M,Laviron M,Berthelot K,Clémenson C,Salomon BL,Combadière C,Deutsch E,Boissonnas A

更新日期：2019-03-01 00:00:00

abstract：:Proneural-to-mesenchymal transition (PMT) is a common process in glioblastoma (GBM) progression that leads to increased radiotherapy resistance. However, the mechanism underlying PMT is poorly understood. Here, we found that tumor-associated macrophages triggered PMT in glioma stem cells (GSC) via small extracellular ...

journal_title：Cancer immunology research

authors： Zhang Z,Xu J,Chen Z,Wang H,Xue H,Yang C,Guo Q,Qi Y,Guo X,Qian M,Wang S,Qiu W,Gao X,Zhao R,Guo X,Li G

更新日期：2020-07-01 00:00:00

abstract：:SLAMF6, a member of the SLAM (signaling lymphocyte activation molecules) family, is a homotypic-binding immune receptor expressed on NK, T, and B lymphocytes. Phosphorylation variance between T-cell subclones prompted us to explore its role in anti melanoma immunity. Using a 203-amino acid sequence of the human SLAMF6...

journal_title：Cancer immunology research

authors： Eisenberg G,Engelstein R,Geiger-Maor A,Hajaj E,Merims S,Frankenburg S,Uzana R,Rutenberg A,Machlenkin A,Frei G,Peretz T,Lotem M

更新日期：2018-02-01 00:00:00

abstract：:Pneumonitis may complicate anti-programmed death-1 (PD-1) therapy, although symptoms usually resolve with steroids. The long-term effects on respiratory function, however, are not well defined. We screened melanoma patients treated with anti-PD-1, with and without ipilimumab (anti-CTLA-4), and identified 31 patients w...

journal_title：Cancer immunology research

authors： Johnson DB,Taylor KB,Cohen JV,Ayoubi N,Haugh AM,Wang DY,Schlick BD,Voorhees AL,Gage KL,Fintelmann FJ,Sullivan RJ,Eroglu Z,Abramson RG

更新日期：2019-11-01 00:00:00

abstract：:High levels of human telomerase reverse transcriptase (hTERT) are detected in more than 85% of human cancers. Immunologic analysis supports that hTERT is a widely applicable target recognized by T cells and can be potentially studied as a broad cancer immunotherapeutic, or a unique line of defense against tumor recurr...

journal_title：Cancer immunology research

authors： Yan J,Pankhong P,Shin TH,Obeng-Adjei N,Morrow MP,Walters JN,Khan AS,Sardesai NY,Weiner DB

更新日期：2013-09-01 00:00:00